{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:15:16Z","timestamp":1773404116601,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The COMET-ICE trial demonstrated that sotrovimab clinically and statistically significantly reduces the risk of all-cause\u2009&gt;\u200924-h hospitalization or death due to any cause among patients with COVID-19 at high risk of disease progression. Patient-reported outcomes are important to capture symptom burden of COVID-19 and assess treatment effectiveness. This study investigated symptoms and their impact over the acute phase of COVID-19 infection among patients on sotrovimab versus placebo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Randomized (1:1), double-blind, multicenter, placebo-controlled, phase 2\/3 study in 57 centers across five countries. Participants were non-hospitalized patients with symptomatic, mild-to-moderate COVID-19 and\u2009\u2265\u20091 baseline risk factor for disease progression (aged\u2009\u2265\u200955\u00a0years or\u2009\u2265\u20091 of the following: diabetes requiring medication, obesity, chronic kidney disease, congestive heart failure, chronic obstructive pulmonary disease, or moderate-to-severe asthma). An intravenous infusion of sotrovimab 500\u00a0mg or placebo was administered on Day 1. The FLU-PRO Plus questionnaire was administered once-daily with 24-h recall from Day 1\u201321, and at Day 29. Intensity and duration of COVID-19 symptoms were determined from area under the curve (AUC) and mean change in total and individual domain scores through Days 7, 14, and 21. Time to symptom alleviation was assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 1057 patients were randomized to sotrovimab (n\u2009=\u2009528) or placebo (n\u2009=\u2009529). At Day 7, mean decrease in FLU-PRO Plus total score (measured by AUC) was statistically significantly greater for patients on sotrovimab (\u20133.05 [95% confidence interval (CI) \u20133.27\u00a0to \u20132.83]) than placebo (\u20131.98 [95% CI \u20132.20\u00a0to \u20131.76]; difference \u20131.07 [95% CI \u20131.38 to\u00a0\u20130.76]; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Significant differences were also observed at Days 14 and 21. A more rapid decline in symptom severity was observed with sotrovimab versus placebo through Week 1 and the first 21\u00a0days post-treatment. By Day 21, 41% of patients on sotrovimab and 34% on placebo reported symptom resolution. In a post-hoc analysis, median time to symptom alleviation was 4 and 6\u00a0days, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Sotrovimab provides significant and rapid improvements in patient-reported COVID-19 symptoms, as measured by the FLU-PRO Plus. These results further show the benefits of sotrovimab in alleviating symptoms among high-risk patients with COVID-19.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> ClinicalTrials.Gov: NCT04545060 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04545060\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04545060<\/jats:ext-link>). Date of registration: September 10, 2020 (retrospectively registered).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-023-00621-8","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T13:01:49Z","timestamp":1694610109000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessment of symptoms in COMET-ICE, a phase 2\/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19"],"prefix":"10.1186","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct04545060","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sacha","family":"Satram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parima","family":"Ghafoori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina M.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-0197","authenticated-orcid":false,"given":"Tom J. H.","family":"Keeley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen J.","family":"Birch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra","family":"Brintziki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Aldinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Lopuski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias H.","family":"Sarkis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne E.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"John H.","family":"Powers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"issue":"7815","key":"621_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto D, Park YJ, Beltramello M et al (2020) Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583(7815):290\u2013295. https:\/\/doi.org\/10.1038\/s41586-020-2349-y","journal-title":"Nature"},{"issue":"7524","key":"621_CR2","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nature13612","volume":"514","author":"SY Ko","year":"2014","unstructured":"Ko SY, Pegu A, Rudicell RS et al (2014) Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514(7524):642\u2013645. https:\/\/doi.org\/10.1038\/nature13612","journal-title":"Nature"},{"issue":"2","key":"621_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nbt.1601","volume":"28","author":"J Zalevsky","year":"2010","unstructured":"Zalevsky J, Chamberlain AK, Horton HM et al (2010) Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28(2):157\u2013159. https:\/\/doi.org\/10.1038\/nbt.1601","journal-title":"Nat Biotechnol"},{"issue":"1","key":"621_CR4","doi-asserted-by":"publisher","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","volume":"15","author":"MR Gaudinski","year":"2018","unstructured":"Gaudinski MR, Coates EE, Houser KV et al (2018) Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults. PLoS Med 15(1):e1002493. https:\/\/doi.org\/10.1371\/journal.pmed.1002493","journal-title":"PLoS Med"},{"key":"621_CR5","doi-asserted-by":"publisher","unstructured":"Cathcart AL, Havenar-Daughton C, Lempp FA et al (2022) The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv  2021.2003.2009.434607. https:\/\/doi.org\/10.1101\/2021.03.09.434607","DOI":"10.1101\/2021.03.09.434607"},{"issue":"13","key":"621_CR6","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1001\/jama.2022.2832","volume":"327","author":"A Gupta","year":"2022","unstructured":"Gupta A, Gonzalez-Rojas Y, Juarez E et al (2022) Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 327(13):1236\u20131246. https:\/\/doi.org\/10.1001\/jama.2022.2832","journal-title":"JAMA"},{"issue":"2","key":"621_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3233\/HAB-200420","volume":"29","author":"AA Gebru","year":"2021","unstructured":"Gebru AA, Birhanu T, Wendimu E et al (2021) Global burden of COVID-19: situational analyis and review. Hum Antibodies 29(2):139\u2013148. https:\/\/doi.org\/10.3233\/HAB-200420","journal-title":"Hum Antibodies"},{"issue":"12","key":"621_CR8","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1001\/jamainternmed.2020.2926","volume":"180","author":"AW Gaffney","year":"2020","unstructured":"Gaffney AW, Himmelstein DU, Woolhandler S (2020) Illness-related work absence in mid-April was highest on record. JAMA Intern Med 180(12):1699\u20131701. https:\/\/doi.org\/10.1001\/jamainternmed.2020.2926","journal-title":"JAMA Intern Med"},{"issue":"12","key":"621_CR9","doi-asserted-by":"publisher","first-page":"ofab517","DOI":"10.1093\/ofid\/ofab517","volume":"8","author":"SA Richard","year":"2021","unstructured":"Richard SA, Epsi NJ, Pollett S et al (2021) Performance of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus) instrument in patients with coronavirus disease 2019. Open Forum Infect Dis 8(12):ofab517. https:\/\/doi.org\/10.1093\/ofid\/ofab517","journal-title":"Open Forum Infect Dis"},{"key":"621_CR10","unstructured":"Centers for Disease Control and Prevention. Similarities and differences between flu and COVID-19. https:\/\/www.cdc.gov\/flu\/symptoms\/flu-vs-covid19.htm. Accessed 23 Nov 2021"},{"key":"621_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-015-1330-0","volume":"16","author":"JH Powers","year":"2016","unstructured":"Powers JH, Guerrero ML, Leidy NK et al (2016) Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza. BMC Infect Dis 16:1. https:\/\/doi.org\/10.1186\/s12879-015-1330-0","journal-title":"BMC Infect Dis"},{"issue":"1","key":"621_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0194599820926473","volume":"163","author":"JY Tong","year":"2020","unstructured":"Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T (2020) The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and meta-analysis. Otolaryngol Head Neck Surg 163(1):3\u201311. https:\/\/doi.org\/10.1177\/0194599820926473","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"6","key":"621_CR13","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s11136-022-03336-3","volume":"32","author":"TJH Keeley","year":"2023","unstructured":"Keeley TJH, Satram S, Ghafoori P et al (2023) Content validity and psychometric properties of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus\u00a9) instrument in patients with COVID-19. Qual Life Res 32(6):1645\u20131657. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9879742\/","journal-title":"Qual Life Res"},{"key":"621_CR14","unstructured":"U.S. Food and Drug Administration. Assessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment. Guidance for industry. https:\/\/www.fda.gov\/media\/142143\/download. Accessed 23 Nov 2021"},{"issue":"1","key":"621_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12955-018-0858-2","volume":"16","author":"T Huo","year":"2018","unstructured":"Huo T, Guo Y, Shenkman E, Muller K (2018) Assessing the reliability of the short form 12 (SF-12) health survey in adults with mental health conditions: a report from the wellness incentive and navigation (WIN) study. Health Qual Life Outcomes 16(1):34. https:\/\/doi.org\/10.1186\/s12955-018-0858-2","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"621_CR16","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3390\/jcm9030661","volume":"9","author":"CH Shah","year":"2020","unstructured":"Shah CH, Brown JD (2020) Reliability and validity of the short-form 12 item version 2 (SF-12v2) health-related quality of life survey and disutilities associated with relevant conditions in the U.S. older adult population. J Clin Med 9(3):661. https:\/\/doi.org\/10.3390\/jcm9030661","journal-title":"J Clin Med"},{"issue":"2","key":"621_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/01.mrr.0000127350.25287.08","volume":"27","author":"RW Bohannon","year":"2004","unstructured":"Bohannon RW, Maljanian R, Landes M (2004) Test\u2013retest reliability of short form (SF)-12 component scores of patients with stroke. Int J Rehabil Res 27(2):149\u2013150. https:\/\/doi.org\/10.1097\/01.mrr.0000127350.25287.08","journal-title":"Int J Rehabil Res"},{"issue":"1","key":"621_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12879-018-3220-8","volume":"18","author":"A Han","year":"2018","unstructured":"Han A, Poon JL, Powers JH 3rd, Leidy NK, Yu R, Memoli MJ (2018) Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model. BMC Infect Dis 18(1):353. https:\/\/doi.org\/10.1186\/s12879-018-3220-8","journal-title":"BMC Infect Dis"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00621-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-023-00621-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00621-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T20:02:56Z","timestamp":1700596976000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-023-00621-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["621"],"URL":"https:\/\/doi.org\/10.1186\/s41687-023-00621-8","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]},"assertion":[{"value":"17 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The COMET-ICE study was conducted in accordance with the principles of the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, applicable International Council for Harmonisation Good Clinical Practice guidelines, and applicable laws and regulations. Written informed consent was provided by all patients prior to study entry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PG, TJHK, HJB, DB, and AL are employees of, and\/or hold stocks\/shares in, GSK. SS, MA, and EA are employees of, and\/or hold stocks\/shares in, Vir Biotechnology, Inc. CMR was an employee of Vir Biotechnology, Inc. at the time of study. JHP III has consulted for Arrevus, Eicos, Eli Lilly, Evofem, Eyecheck, Fuji, Gilead, Johnson & Johnson, Microbion, OPKO, Otsuka, Resolve, Romark, Shinogi, SpineBioPharma, and UTIlity, outside the submitted work, and for GSK and Vir Biotechnology, Inc. for the submitted work. AG and AES have acted as trial investigators for Vir Biotechnology, Inc. and received non-financial support from Vir Biotechnology, Inc. during the conduct of the study. EHS has acted as a trial investigator for Vir Biotechnology, Inc. and received non-financial support from Vir Biotechnology, Inc. during the conduct of the study; has received research support from AbbVie, Eisai, Eli Lilly, GSK, Ironshore, Otsuka, and Vir Biotechnology, Inc.; and served on speaker bureaus for AbbVie, Janssen, and Teva.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}